|
Market Closed -
NYSE
05:00:00 17/11/2026 HKT
|
5-day change | 1st Jan Change | ||
| 3.030 USD | -0.66% |
|
+17.90% | +68.33% |
| 11-11 | Protalix BioTherapeutics, Inc. Reaffirms Earnings Guidance for the Full Year 2026 | CI |
| 11-10 | Protalix BioTherapeutics, Inc., Q3 2026 Earnings Call, Nov 10, 2026 |
Company Valuation: Protalix BioTherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 257.2 | - | - |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 77.66% | - | - |
| Enterprise Value (EV) | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 257.2 | 257.2 | 257.2 |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 77.66% | 0% | 0% |
| P/E | -1.34x | -4.42x | 19.8x | 47x | -22.5x | 10.9x | -305x | 43.6x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | -0.8x | 0x | -0x | 3x | -0x |
| Capitalization / Revenue | 0.99x | 1.46x | 1.98x | 2.59x | 2.74x | 2.91x | 3.37x | 3.34x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.91x | 3.37x | 3.34x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | 0x | -0x | 9.81x | -150x | 40x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.62 | -0.31 | 0.09 | 0.04 | -0.08 | 0.28 | -0.01 | 0.07 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.35 | 47.64 | 65.49 | 53.4 | 52.74 | 88.42 | 76.28 | 76.97 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.46 | -13.01 | 10.46 | 3.917 | -5.5 | 26.21 | -1.719 | 6.426 |
| Net income 1 | -27.58 | -14.93 | 8.312 | 2.932 | -6.604 | 23.02 | -1.087 | 6.231 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 0.832 | 1.370 | 1.780 | 1.880 | 1.800 | 3.050 | 3.050 | 3.050 |
| Nbr of stocks (in thousands) | 45,557 | 50,666 | 72,952 | 73,634 | 80,421 | 84,319 | - | - |
| Announcement Date | 31/3/22 | 27/2/23 | 14/3/24 | 17/3/25 | 18/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 10.89x | - | - | - | 257M | ||
| 42.25x | 14.3x | 30.31x | 0.47% | 1,286B | ||
| 41.82x | 7.01x | 19.73x | 1.87% | 688B | ||
| 37.62x | 8.63x | 17.81x | 2.34% | 521B | ||
| 21.75x | 5.27x | 13.2x | 2.48% | 386B | ||
| 104.88x | 5.98x | 25.49x | 2.3% | 364B | ||
| 24x | 5.82x | 14.17x | 2.73% | 302B | ||
| 24.25x | 4.85x | 13.63x | 1.8% | 287B | ||
| 24.04x | 7.38x | 13.56x | 2.17% | 252B | ||
| -39.49x | 7.32x | 46.07x | 1.96% | 208B | ||
| Average | 29.20x | 7.40x | 21.55x | 2.01% | 429B | |
| Weighted average by Cap. | 37.57x | 8.95x | 22.68x | 1.68% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PLX Stock
- Valuation Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
















